Peripheral arterial disease (PAD) is related to morbidity and mortality from other types of atherosclerotic disease, even after adjustment for known common risk factors.[21]Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015 Apr 24;116(9):1509-26.
http://www.ncbi.nlm.nih.gov/pubmed/25908725?tool=bestpractice.com
This explains the importance of general cardiovascular prevention in patients with PAD.[2]Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.
https://www.sciencedirect.com/science/article/pii/S0735109724003814
http://www.ncbi.nlm.nih.gov/pubmed/38752899?tool=bestpractice.com
Ankle-brachial index (ABI) is a marker for cardiovascular events beyond the diagnosis of PAD.[1]Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-700.
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
http://www.ncbi.nlm.nih.gov/pubmed/39210722?tool=bestpractice.com
A more rapid deterioration in ABI carries a worse prognosis for all-cause mortality and cardiovascular disease mortality, independent of baseline ABI and potential confounding variables.[21]Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015 Apr 24;116(9):1509-26.
http://www.ncbi.nlm.nih.gov/pubmed/25908725?tool=bestpractice.com
Presence of hypertension has been associated with a longitudinal decline in ABI.[2]Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.
https://www.sciencedirect.com/science/article/pii/S0735109724003814
http://www.ncbi.nlm.nih.gov/pubmed/38752899?tool=bestpractice.com
Claudication
For the most part, claudication symptoms remain stable and do not worsen rapidly. Two clinical risk factors, significantly reduced ABI and diabetes, increase the risk for chronic limb ischaemia.[2]Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.
https://www.sciencedirect.com/science/article/pii/S0735109724003814
http://www.ncbi.nlm.nih.gov/pubmed/38752899?tool=bestpractice.com
Critical limb ischaemia
At 1 year, 25% of patients with critical limb ischaemia will have died and 30% will have undergone amputation. At 5 years, more than 60% of patients with critical limb ischaemia will have died.[110]Davies MG. Criticial limb ischemia: epidemiology. Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):10-4.
http://www.ncbi.nlm.nih.gov/pubmed/23342182?tool=bestpractice.com
Acute limb ischaemia
The long-term prognosis for the limb is dependent on speed and completeness of revascularisation prior to onset of permanent tissue and nerve damage.
Impact of common comorbidities
The presence of specific comorbidities and risk factors increases the risk for major adverse cardiovascular events and major adverse limb events in those with PAD. Multisociety US guidelines recommend that patients with PAD should be assessed for these risk amplifiers when developing patient-focused treatment recommendations.[2]Writing Committee Members; Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.
https://www.sciencedirect.com/science/article/pii/S0735109724003814
http://www.ncbi.nlm.nih.gov/pubmed/38752899?tool=bestpractice.com
Hypertension
Dyslipidaemia
Diabetes
Chronic kidney disease/end-stage renal disease
Depression
Atherosclerotic disease in more than one vascular bed (PAD, coronary artery disease, cerebrovascular disease)
Microvascular disease (retinopathy, neuropathy, nephropathy)
Current smoking/tobacco use
Older age and geriatric syndromes (frailty, mobility impairment, sarcopenia, malnutrition)
Patients with PAD and comorbid heart failure have an increased risk of major adverse cardiovascular events and all-cause mortality.[1]Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-700.
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
http://www.ncbi.nlm.nih.gov/pubmed/39210722?tool=bestpractice.com